...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Medical oncology >Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients: a single institute experience
【24h】

Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients: a single institute experience

机译：每两周一次吉西他滨和低剂量顺铂治疗局部晚期或转移性胰腺癌患者的单一机构经验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Gemcitabine in combination with low-dose cisplatin has shown promising activity in pancreatic cancer with manageable toxicities. The purpose of this study is to assess the activity of a combination of gemcitabine and low-dose cisplatin in the first-line treatment of metastatic and locally advanced pancreatic cancer patients. We conducted a retrospective analysis of all patients diagnosed with metastatic and locally advanced pancreatic cancer who received a combination of gemcitabine and cisplatin in the first-line setting. Patients with baseline cytopenias and elevated liver function tests were included. Patients received cisplatin at 20 mg per square meter followed by gemcitabine at a dose of 1000 mg per square meter at fixed dose rate every 2 weeks. Patients were treated until disease progression or unacceptable toxicities. A total of 58 patients were included in the analysis. The median progression-free survival was 4.4 months [95 % confidence interval (CI) 3.6-6.4], and median overall survival was 6.7 months (95 % CI 4.4-10.9). Thirty-eight patients (66 %) experienced at least one grade 3 or 4 toxicity. The most common grade 3 or 4 toxicity was hematologic toxicity (25 patients, 43 %). Biweekly fixed dose rate gemcitabine combined with low-dose cisplatin shows interesting activity in advanced pancreatic cancer. This regimen is an acceptable alternative for patients ineligible for gemcitabine plus nab-paclitaxel (i.e., those with elevated bilirubin at baseline) or clinical trials. Additionally, this regimen should be considered as a first-line option for those patients with breast cancer susceptibility gene mutations (BRCA1 and/or BRCA2).
机译：吉西他滨联合小剂量顺铂在具有可控毒性的胰腺癌中显示出令人鼓舞的活性。这项研究的目的是评估吉西他滨和小剂量顺铂联合在转移性和局部晚期胰腺癌患者的一线治疗中的活性。我们对一线接受吉西他滨和顺铂联合治疗的所有诊断为转移性和局部晚期胰腺癌的患者进行了回顾性分析。包括基线血细胞减少和肝功能检查升高的患者。患者每2周接受固定剂量率的每平方米20毫克顺铂，然后接受每平方米1000毫克吉西他滨的剂量。治疗患者直至疾病进展或出现不可接受的毒性。分析中总共包括58位患者。中位无进展生存期为4.4个月[95％置信区间（CI）3.6-6.4]，中位总生存期为6.7个月（95％CI 4.4-10.9）。 38名患者（66％）经历了至少一种3级或4级毒性。最常见的3或4级毒性是血液学毒性（25例患者，43％）。双周固定剂量率吉西他滨联合小剂量顺铂在晚期胰腺癌中显示出有趣的活性。对于不适合使用吉西他滨加nab-紫杉醇的患者（即基线时胆红素升高的患者）或临床试验，该方案是可接受的替代方案。此外，对于患有乳腺癌易感基因突变（BRCA1和/或BRCA2）的患者，该方案应被视为一线选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号